Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 18650 | 475 | 37.3 | 83% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | MHC NONRESTRICTED CYTOTOXICITY | Author keyword | 2 | 67% | 0% | 2 |
| 2 | HISTAMINE DIHYDROCHLORIDE | Author keyword | 2 | 36% | 1% | 4 |
| 3 | BOWYER ONCOL | Address | 1 | 50% | 0% | 2 |
| 4 | IMMUNOL BIOTHER Y PROGRAM | Address | 1 | 100% | 0% | 2 |
| 5 | LYMPHOCYTE CELL CULTURE | Author keyword | 1 | 40% | 0% | 2 |
| 6 | LAK ACTIVITY | Author keyword | 1 | 20% | 1% | 4 |
| 7 | ACTIVATED NATURAL KILLER A NK CELLS | Author keyword | 1 | 50% | 0% | 1 |
| 8 | ADVANCED AML | Author keyword | 1 | 50% | 0% | 1 |
| 9 | ANTIBODY DIRECTED THERAPY | Author keyword | 1 | 50% | 0% | 1 |
| 10 | ANTILEUKEMIA CYTOTOXICITY | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | POTENT GRAFT | 23 | 86% | 3% | 12 |
| 2 | DOSE CHEMO RADIOTHERAPY | 15 | 68% | 3% | 13 |
| 3 | LAK GENERATION | 8 | 75% | 1% | 6 |
| 4 | DOSE RECOMBINANT INTERLEUKIN 2 | 6 | 15% | 8% | 39 |
| 5 | CONSOLIDATIVE IMMUNOTHERAPY | 6 | 100% | 1% | 4 |
| 6 | FRESH HUMAN LEUKEMIA | 6 | 100% | 1% | 4 |
| 7 | KILLER CELL GENERATION | 6 | 100% | 1% | 4 |
| 8 | ACUTE LEUKEMIA PATIENTS | 4 | 38% | 2% | 9 |
| 9 | CYTOTOXIC EFFECTORS | 4 | 75% | 1% | 3 |
| 10 | CLONOGENIC GROWTH | 3 | 42% | 1% | 5 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Post-consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML | 2009 | 22 | 67 | 51% |
| Histamine in cancer immunotherapy: A preclinical background | 2002 | 38 | 39 | 46% |
| Interleukin-2 and leukemia | 1998 | 21 | 46 | 61% |
| Histamine Dihydrochloride In the Management of Acute Myeloid Leukaemia | 2011 | 10 | 43 | 40% |
| Histamine and interleukin-2 in acute myelogenous leukemia | 1997 | 19 | 35 | 57% |
| Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia | 2010 | 18 | 87 | 29% |
| DOES INTERLEUKIN-2 HAVE A ROLE IN THE MANAGEMENT OF ACUTE-LEUKEMIA | 1993 | 43 | 64 | 47% |
| Histamine: A novel approach to cancer immunotherapy | 2000 | 26 | 48 | 35% |
| Natural killer cells in haematopoietic stem cell transplantation | 2003 | 7 | 26 | 46% |
| Use of interleukin-2 in the management of haematological malignancies - Focus on minimal residual disease | 1999 | 3 | 63 | 63% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | BOWYER ONCOL | 1 | 50% | 0.4% | 2 |
| 2 | IMMUNOL BIOTHER Y PROGRAM | 1 | 100% | 0.4% | 2 |
| 3 | ASSOC ITALIANA RIC CANC | 1 | 50% | 0.2% | 1 |
| 4 | FOR UNGS A | 1 | 50% | 0.2% | 1 |
| 5 | HARVARD MED HEMATOL ONCOL | 1 | 50% | 0.2% | 1 |
| 6 | HEMATOL SURG | 1 | 50% | 0.2% | 1 |
| 7 | IMMUNOL TUMORS | 1 | 50% | 0.2% | 1 |
| 8 | STATE POST EDUC | 1 | 50% | 0.2% | 1 |
| 9 | HEMATOL ONCOL 332 N LAUDERDALE | 1 | 22% | 0.4% | 2 |
| 10 | SECT BONE MARROW TRANSPLANT CELL THER Y | 0 | 13% | 0.6% | 3 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000246856 | INTERLEUKIN 2//LYMPHOKINE ACTIVATED KILLER CELLS//RECOMBINANT INTERLEUKIN 2 |
| 2 | 0.0000166235 | LYMPHOCYTE RECOVERY//IMMUNE RECONSTITUTION//BMT RECIPIENTS |
| 3 | 0.0000143886 | PRAME//LEUKEMIA ASSOCIATED ANTIGENS//UNIT 900 |
| 4 | 0.0000137382 | CD3 ZETA//ORAL BIOL ORAL MED//ZETA CHAIN |
| 5 | 0.0000120827 | REDUCED INTENSITY CONDITIONING//DONOR LYMPHOCYTE INFUSION//REDUCED INTENSITY |
| 6 | 0.0000119470 | ENGRAFTMENT SYNDROME//AUTOLOGOUS GRAFT VERSUS HOST DISEASE//AUTOLOGOUS GVHD |
| 7 | 0.0000113053 | CXXC5//THEOPHYLLAMINE//BIOCHIP ARRAY |
| 8 | 0.0000110914 | CYTOKINE INDUCED KILLER CELLS//CIK CELLS//CYTOKINE INDUCED KILLER CELL |
| 9 | 0.0000108882 | MHC AF//IMMUNODIAG//CARBOHYDRATE COMPONENT |
| 10 | 0.0000105247 | AUXOTROPHIC EDWARDSIELLA TARDA MUTANT//CAS 51 45 6//CIMETIDINE THERAPEUTIC USE |